The lessons of Vioxx—drug safety and sales
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
In May, the Government Reform Committee of the U.S. House of Representatives held a hearing that explored how drugs with serious safety issues can remain so popular for so long. Representative Henry Waxman describes how what was learned illuminated the practices that pharmaceutical manufacturers use to promote their products to physicians.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“It was not until four years of long-term clinical studies that it became evident that the risk of heart attack and stroke was actually two-fold higher with Vioxx compared to the control group [3].”
From Cardiovascular disease models: A game changing paradigm in drug discovery and screening (2019) · cites this paper as [3]
Citations
Cites
Graham, D. J., Campen, D., Hui, R., Spence, M., Cheetham, C., Levy, G., Shoor, S., & Ray, W. A. (2005) · The Lancet · doi:10.1016/s0140-6736(05)17864-7 · Cited by 913
Dai, C., Stafford, R. S., & Alexander, G. C. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.2.171 · Cited by 117
Cited by
Reporting bias in medical research - a narrative review
McGauran, N., Wieseler, B., Kreis, J., Schüler, Y.-B., Kölsch, H., & Kaiser, T. (2010) · Trials · doi:10.1186/1745-6215-11-37 · Cited by 452
THE POLITICS OF PUBLIC HEALTH POLICY
Oliver, T. R. (2006) · Annual Review of Public Health · doi:10.1146/annurev.publhealth.25.101802.123126 · Cited by 338
Cyclooxygenase Inhibition and Cardiovascular Risk
Antman, E. M., DeMets, D., & Loscalzo, J. (2005) · Circulation · doi:10.1161/circulationaha.105.568451 · Cited by 282
Hershman, D., Neugut, A. I., Jacobson, J. S., Wang, J., Tsai, W.-Y., McBride, R., Bennett, C. L., & Grann, V. R. (2007) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djk028 · Cited by 279
Cardiovascular disease models: A game changing paradigm in drug discovery and screening
Savoji, H., Mohammadi, M. H., Rafatian, N., Toroghi, M. K., Wang, E. Y., Zhao, Y., Korolj, A., Ahadian, S., & Radisic, M. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2018.09.036 · Cited by 223
Metadata
- Authors
- Waxman, H. A.
- Corresponding author
- Waxman, Henry A.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2005-06-23
- Volume
- 352
- Issue
- 25
- Pages
- 2576-2578
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1994883059
- Cited by
- 99
- References
- 2
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 3 · 2023: 2 · 2022: 1 · 2021: 3 · 2020: 5 · 2019: 5 · 2018: 5 · 2017: 3 · 2016: 4 · 2015: 4 · 2014: 1 · 2013: 3 · 2012: 7
- FWCI
- 7.91
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- DigitalGeorgetown (Georgetown University Library) (submittedVersion)
- Topics
- Health Sciences › Nursing › Issues, ethics and legal aspects › Pharmaceutical industry and healthcare
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Keywords
- rofecoxib, drug safety, pharmaceutical marketing, pharmaceutical industry, drug approval, adverse drug reactions, congressional hearings
- MeSH terms
- Anti-Inflammatory Agents, Non-Steroidal, Arthritis, Drug Evaluation, Drug Industry, Gastrointestinal Diseases, Humans, Lactones, Myocardial Infarction, Naproxen, Sulfones, United States, Scientific Misconduct, Cyclooxygenase Inhibitors, Marketing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The lessons of Vioxx—drug safety and sales. https://app.cochat.ai/papers/10.1056/nejmp058136
- The paper
- Waxman, H. A. (2005). The lessons of Vioxx—drug safety and sales. New England Journal of Medicine. https://doi.org/10.1056/nejmp058136
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.